1. Home
  2. ELDN vs VUZI Comparison

ELDN vs VUZI Comparison

Compare ELDN & VUZI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELDN
  • VUZI
  • Stock Information
  • Founded
  • ELDN 2004
  • VUZI 1997
  • Country
  • ELDN United States
  • VUZI United States
  • Employees
  • ELDN N/A
  • VUZI N/A
  • Industry
  • ELDN Biotechnology: Pharmaceutical Preparations
  • VUZI Industrial Machinery/Components
  • Sector
  • ELDN Health Care
  • VUZI Technology
  • Exchange
  • ELDN Nasdaq
  • VUZI Nasdaq
  • Market Cap
  • ELDN 178.4M
  • VUZI 122.9M
  • IPO Year
  • ELDN N/A
  • VUZI N/A
  • Fundamental
  • Price
  • ELDN $3.17
  • VUZI $1.82
  • Analyst Decision
  • ELDN Strong Buy
  • VUZI Strong Buy
  • Analyst Count
  • ELDN 1
  • VUZI 1
  • Target Price
  • ELDN $16.00
  • VUZI $2.00
  • AVG Volume (30 Days)
  • ELDN 150.4K
  • VUZI 1.1M
  • Earning Date
  • ELDN 05-20-2025
  • VUZI 05-16-2025
  • Dividend Yield
  • ELDN N/A
  • VUZI N/A
  • EPS Growth
  • ELDN N/A
  • VUZI N/A
  • EPS
  • ELDN N/A
  • VUZI N/A
  • Revenue
  • ELDN N/A
  • VUZI $5,754,556.00
  • Revenue This Year
  • ELDN N/A
  • VUZI $43.59
  • Revenue Next Year
  • ELDN N/A
  • VUZI $55.00
  • P/E Ratio
  • ELDN N/A
  • VUZI N/A
  • Revenue Growth
  • ELDN N/A
  • VUZI N/A
  • 52 Week Low
  • ELDN $2.00
  • VUZI $0.83
  • 52 Week High
  • ELDN $5.54
  • VUZI $5.79
  • Technical
  • Relative Strength Index (RSI)
  • ELDN 48.82
  • VUZI 45.64
  • Support Level
  • ELDN $2.85
  • VUZI $1.71
  • Resistance Level
  • ELDN $3.51
  • VUZI $2.20
  • Average True Range (ATR)
  • ELDN 0.25
  • VUZI 0.15
  • MACD
  • ELDN 0.01
  • VUZI 0.03
  • Stochastic Oscillator
  • ELDN 45.07
  • VUZI 41.54

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

About VUZI Vuzix Corporation

Vuzix Corp is engaged in the design, manufacturing, marketing, and selling of Smart Glasses and Augmented Reality (AR) technologies and products for the enterprise, medical, defense, and consumer markets. Its products include head-mounted (or HMDs or heads-up displays or HUDs) smart personal display and wearable computing devices that offer users a portable high-quality viewing experience, provide solutions for mobility, wearable displays, and augmented reality, as well as OEM waveguide optical components and display engines. Geographically, the company generates a majority of its revenue from the United States and also has a presence in Japan, Netherlands, and other countries.

Share on Social Networks: